$10.460
-0.496 (-4.74%)收盤時
EIKN 同業比較
In the context of the broader market, EIKN competes directly with industry leaders such as ASPI and BLSM. With a market capitalization of $589.32M, it holds a significant position in the sector. When comparing efficiency, EIKN's gross margin of N/A stands against ASPI's 28.89% and BLSM's N/A. Such benchmarking helps identify whether Eikon Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Eikon Therapeutics Inc 財務表現
Eikon Therapeutics has reported substantial net losses, with Q2 2026 net income of -88,409,000 USD and a current ratio of 9.89, indicating liquidity issues. The company has a forward P/E of 0, reflecting no expected earnings growth in the near term.
Financials
FY2026Q2
YoY:
-14.82%
-93.39M
Operating Profit
FY2026Q2
YoY:
-15.97%
-88.41M
Net Income after Tax
FY2026Q2
YoY:
-95.59%
-1.63
EPS - Diluted
FY2026Q2
-65.21M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。